<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04548427</url>
  </required_header>
  <id_info>
    <org_study_id>A100_01DED1924</org_study_id>
    <nct_id>NCT04548427</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of CKD-352</brief_title>
  <official_title>Active Controlled, Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-352 Eye Drops in Patients With Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of CKD-352 in patients with&#xD;
      dry eye disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Active controlled, randomized, double-blind, multi-center, phase 3 trial to evaluate the&#xD;
      efficacy and safety of CKD-352 eye drops in patients with dry eye disease&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 22, 2020</start_date>
  <completion_date type="Actual">May 7, 2021</completion_date>
  <primary_completion_date type="Actual">May 7, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Corneal Staining from Baseline and at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Corneal Staining from Baseline and at Week 2</measure>
    <time_frame>Baseline, Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Conjunctival Staining from Baseline and at Week 2,4</measure>
    <time_frame>Baseline, Week 2,4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Tear Break-up Time from Baseline and at Week 2, 4</measure>
    <time_frame>Baseline, Week 2,4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Schirmer I Test from Baseline and at Week 2, 4</measure>
    <time_frame>Baseline, Week 2,4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Ocular Surface Disease Index from Baseline and at week 2, 4</measure>
    <time_frame>Baseline, Week 2,4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">283</enrollment>
  <condition>Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>CKD-352</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Diquafosol Sodium 3%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-352</intervention_name>
    <description>Eye Drop</description>
    <arm_group_label>CKD-352</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diquafosol Sodium 3%</intervention_name>
    <description>Eye Drop</description>
    <arm_group_label>Diquafosol Sodium 3%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. More than the age of 19 years old&#xD;
&#xD;
          2. Subjects with dry eye symptoms for at least 3 month&#xD;
&#xD;
          3. Subjects who sign on an informed consent form willingly&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have clinically significant ocular surface diseases, abnormal corneal&#xD;
             susceptibility and abnormal epiphora&#xD;
&#xD;
          2. Subjects who have clinically significant medical history of ocular disability&#xD;
&#xD;
          3. Subjects who have malignant tumor within 5 years&#xD;
&#xD;
          4. Subjects with known hypersensitivity to investigational product&#xD;
&#xD;
          5. Women who are nursing, pregnant or planning pregnancy during the study&#xD;
&#xD;
          6. Subjects who have received any other investigational product&#xD;
&#xD;
          7. Impossible subjects who participate in clinical trial by investigator's decision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong Su Lee, M.D, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Pusan National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry Eye Disease</keyword>
  <keyword>CKD-352</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

